Literature DB >> 29152479

Appropriate surgical therapy for patients with hepatocellular carcinoma beyond Milan criteria.

Kwang Yeol Paik1.   

Abstract

Entities:  

Year:  2017        PMID： 29152479      PMCID： PMC5673764          DOI： 10.21037/hbsn.2017.05.06

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  5 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

Review 2.  Criteria for liver transplantation for HCC: what should the limits be?

Authors:  Mauricio F Silva; Morris Sherman
Journal:  J Hepatol       Date:  2011-06-27       Impact factor: 25.083

Review 3.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Therapeutic options for intermediate-advanced hepatocellular carcinoma.

Authors:  Zong-Ming Zhang; Jin-Xing Guo; Zi-Chao Zhang; Nan Jiang; Zhen-Ya Zhang; Li-Jie Pan
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

5.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

Authors:  Vincenzo Mazzaferro; Josep M Llovet; Rosalba Miceli; Sherrie Bhoori; Marcello Schiavo; Luigi Mariani; Tiziana Camerini; Sasan Roayaie; Myron E Schwartz; Gian Luca Grazi; René Adam; Peter Neuhaus; Mauro Salizzoni; Jordi Bruix; Alejandro Forner; Luciano De Carlis; Umberto Cillo; Andrew K Burroughs; Roberto Troisi; Massimo Rossi; Giorgio E Gerunda; Jan Lerut; Jacques Belghiti; Ilka Boin; Jean Gugenheim; Fedja Rochling; Bart Van Hoek; Pietro Majno
Journal:  Lancet Oncol       Date:  2008-12-04       Impact factor: 41.316
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.